XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 39.8

Change

-1.10 (-2.69)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-3.12 (-2.32%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.56 (-2.45%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.83 (-2.73%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

-2.55 (-3.06%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.39 (-1.91%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-2.77 (-2.75%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.78 (-2.66%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.83 (-3.00%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.43 (-2.50%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.64 (-3.42%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.69 % 0.00 %

-0.74 (-2.60%)

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.42% 29% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.42% 29% F 24% F
Trailing 12 Months  
Capital Gain -3.40% 76% C+ 36% F
Dividend Return 1.23% 94% A 25% F
Total Return -2.17% 76% C+ 31% F
Trailing 5 Years  
Capital Gain -7.81% 29% F 28% F
Dividend Return 5.78% 68% D+ 12% F
Total Return -2.02% 33% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -3.87% 33% F 19% F
Dividend Return -3.05% 33% F 13% F
Total Return 0.82% 68% D+ 20% F
Risk Return Profile  
Volatility (Standard Deviation) 12.93% 67% D+ 70% C-
Risk Adjusted Return -23.59% 24% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.